We found that LYRM4-AS1 was an independent risk factor for predicting the prognosis of patients with glioma (Table 2) and high LYRM4-AS1 expression had a worse prognosis than patients with low LYRM4-AS1 expression (Fig. 3). This evidence concerns the gene LYRM4 and central nervous system cancer.